Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3693041 | 0.97 | BRD4 (0.39) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12994229 | 0.87 | BRD4 (0.36) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5118396 | 0.85 | BRD4 (0.42) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14441118 | 0.85 | BRD4 (0.35) | BRD4ALDH1A1NPSR1HSP90AA1 | |
| SCHEMBL3244631 | 0.83 | CHRNB2 (0.40) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5727783 | 0.82 | BRD4 (0.50) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1010815 | 0.82 | BRD4 (0.39) | BRD4KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL14446813 | 0.81 | TP53 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14014829 | 0.81 | CHRNB2 (0.39) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7319111 | 0.80 | MAPK1 (0.47) | BRD4KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | disclosed |
| EP-1861397-A2 | PRODUCTION OF DOLASETRON | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság (HU) | 2007-12-05 | — | — | EP | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007081890-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
| EP-0339669-A1 | Process for preparing indole-3-carboxylic acid esters of trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | DHPS, ALG8, DDOST | BRD4 4552/4885CHRNB2 2979/4885CHRNA4 3398/4885 |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | CYP4A11, CYP3A43, VKORC1 | BRD4 3815/4885CHRNB2 1234/4885CHRNA4 819/4885 |
| US-20070203175-A1 | Productioin of dolasetron | DDOST, ALG8, DUT | BRD4 4178/4885CHRNB2 2266/4885CHRNA4 2568/4885 |
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | BRD4 4383/4885CHRNB2 3222/4885CHRNA4 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.